Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZE46-0134 in healthy volunteers
NCT06399315Phase 1Completed
- Sponsor
- Lomond Therapeutics
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lomonitinib in acute myeloid leukemia (AML) (14 arms), sponsored by Lomond Therapeutics. Primary endpoint: Plasma concentration of ZE46-0134 at 10 days. Started Jul 2023; status: completed.
02
Drugs
lomonitinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06399315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399315.